Lb Pharmaceuticals (LBRX) Cash from Financing Activities (2025 - 2026)
Lb Pharmaceuticals' quarterly Cash from Financing Activities came in at $93.8 million in Q1 2026, up 8119.74% quarter-over-quarter from -$1.2 million in Q4 2025.
Lb Pharmaceuticals has reported Cash from Financing Activities for 2 years, with the latest figure at $93.8 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to $93.8 million; the trailing twelve-month figure through Mar 2026 stood at $92.7 million (changed N/A YoY), and the FY2025 full-year result was $302.6 million, up 689.67% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $93.8 million, up from -$1.2 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $93.8 million in Q1 2026, with the low at -$1.2 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Lb Pharmaceuticals | 789.92 Mn | 789.92 Mn | - | 93.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93.83 Mn |
| Mar 31, 2026 | 93.83 Mn |
| Dec 31, 2025 | -1.17 Mn |
| Dec 31, 2025 | -1.17 Mn |